Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: a randomized controlled phase 2a trial

Overview of attention for article published in Nature Medicine, March 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 36 news outlets
blogs: 3 blogs
twitter: 40 X users
facebook: 1 Facebook page

wikipedia: 1 Wikipedia page
video: 1 YouTube creator
bluesky: 5 Bluesky users

Readers on

mendeley: 95 Mendeley

So far, Altmetric has seen 81 news stories from 36 outlets.

Longeveron to Participate in Three Longevity/Aging Investment Conferences

BioSpace, 01 Oct 2026

New Data Analysis from Phase 2a Clinical Trial in Alzheimer’s Disease (AD) Indicating That Laromestrocel Treatment May Reduce…

Longeveron to Participate in Three Longevity/Aging Investment Conferences

Global Business Watch, 30 Sep 2026

New Data Analysis from Phase 2a Clinical Trial in Alzheimer’s Disease (AD) Indicating That Laromestrocel Treatment May Reduce…

Longeveron to Participate in Three Longevity/Aging Investment Conferences

Journal of Business News, 30 Sep 2026

New Data Analysis from Phase 2a Clinical Trial in Alzheimer’s Disease (AD) Indicating That Laromestrocel Treatment May Reduce…

Longeveron to Participate in Three Longevity/Aging Investment Conferences

The Manila Times, 30 Sep 2026

New Data Analysis from Phase 2a Clinical Trial in Alzheimer’s Disease (AD) Indicating That Laromestrocel Treatment May Reduce…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 77 additional news stories.